论文信息 - The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures - 字舞流文

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

I. Huys | E. Allocati | A. Vulto | B. Godman | R. Adams | Silvia Stockinger | O. Laius | Jurij Fürst | G. Selke | L. Voncina | K. Tachkov | S. Keuerleber | M. Dimitrova | Iris Hoxha | Vanda Marković-Peković | J. Slabý | A. Jakupi | Ø. Melien | I. Mardare | C. Zara | V. Kourafalos | J. Martikainen | P. Vella Bonanno | G. Achniotou | Einar Magnússon | R. Joppi | D. Meshkov | T. Novakovic | Ieva Greičiūtė-Kuprijanov | V. V. Palčevski | Anita Viksna | R. Plisko | Admir Malaj | Evelien Moorkens | Sarah Mörtenhuber | Leona Popelková | Kateřina Kohoutová | Dorthe Bartels | R. Einarsdóttir | Vincent Suttorp | N. Grubiša | G. Befrits | R. Puckett | A. Viksna